Bio Association Hosts '2023 Global IR @JPM' for Investment Attraction

On the 8th, the 3rd Global IR@JPM event held at the Nasdaq Entrepreneurial Center. / Photo by Korea Bio Association

[Asia Economy Reporter Myung-hwan Lee] The Korea Bio Association announced on the 12th that it held the '2023 Global IR @JPM' event on the 8th (local time) in San Francisco, USA, as a side event of the JP Morgan Healthcare Conference.

At the event, 12 pre-selected domestic and overseas bio startups participated and conducted IR presentations. Additionally, industry experts and investors in the bio sector held a panel discussion.

Among the 12 IR companies participating domestically and internationally, six member companies of the Bio Association gave presentations. Their topics included ▲ stem cell therapy pipeline for acute pancreatitis and alimentary tract host diseases (SCM Life Sciences) ▲ site-selective antibody-binding linker platform technology and antibody-drug conjugate development based on it (Aptis) ▲ precision anticancer drugs and respiratory virus therapeutics development (Abion) ▲ immune-oncology and allergy treatment pipelines and dual-fusion protein development using next-generation drug development platforms (GI Innovation) ▲ development and production of anticancer drugs loaded with new antigens on dendritic cell membrane-based nanostructures (Fortuga Bio) ▲ AI-based major vital sign analysis, diagnostic support platform manufacturing, and chronic disease fields (Huino).

In the panel discussion, global investment firms from home and abroad shared opinions on the bio market, which has been stagnant since COVID-19, led by Jeff Kramer, editor of BioCentury. They specifically discussed the global competitiveness of domestic bio companies from the perspective of investors. Investment firms such as CBC Group, J&J Innovation, LYFE Capital, RM Global, KB Investment, and Daol Investment attended the event.

In the case study session on cross-national patent transactions, Janssen and Yuhan Corporation introduced previously unreported cases, including the reasons for their cooperation as global partners, the time taken to reach agreements, difficulties during negotiations, and advice for domestic and global bio companies seeking technology transfer partners.

The '2023 Global IR @JPM' hosted by the Korea Bio Association is a side event of the JP Morgan Healthcare Conference. It provides domestic bio startups with opportunities for global investment attraction and networking, and global bio startups with opportunities to explore entry into the domestic market. For the past two years, the event was held online due to COVID-19, and this year it was held offline for the first time.

Meanwhile, the association operates the 'Global Mingle' program to support domestic bio companies in technology development, investment attraction, overseas expansion, and global network building. It also continues to promote exchanges with various advanced bio companies worldwide.

This content was produced with the assistance of AI translation services.